sector intelligence brief
Post-pandemic resilience spending is maturing into sustained investment. Where medical device, pharmaceutical, and digital health procurement is growing across Europe — and what suppliers need to know to compete.
published march 2026 — based on analysis of 156,000+ procedures
Healthcare is the third-largest procurement sector in Europe by procedure count and the largest by total estimated value when hospital infrastructure is included.
Post-pandemic resilience programmes have added an estimated EUR 18 billion in incremental annual spending, much of it recurring.
Electronic health records, telemedicine, and clinical decision support systems are the fastest-growing sub-categories within healthcare procurement.
This report analyses 156,000+ procurement procedures classified under CPV division 33 (medical equipment, pharmaceuticals, and personal care products) and CPV division 85 (health and social work services), published between January 2024 and February 2026 across TED and 25+ national procurement platforms. All data is normalised against Duke's unified procurement model, which standardises buyer identifiers, CPV classification codes, lot structures, and award outcomes. Monetary values are converted to EUR using ECB reference rates at publication date.
European healthcare procurement has undergone a structural transformation since 2020. What began as emergency pandemic spending has matured into sustained investment in resilience, modernisation, and supply chain diversification. Duke's analysis of 156,000+ procedures across CPV 33 and 85 reveals an estimated annual market of EUR 112 billion, making healthcare the largest procurement sector by value in the EU. This figure encompasses medical devices and equipment, pharmaceutical products, clinical and laboratory services, digital health systems, and facilities management for healthcare institutions.
The post-COVID legacy is visible across every sub-category. Strategic stockpiling programmes have created new recurring procurement streams for personal protective equipment, diagnostic reagents, and critical medicines. Hospital modernisation programmes funded by national recovery plans (and the EU Recovery and Resilience Facility) are driving demand for imaging equipment, surgical systems, and ward infrastructure. Crucially, these are not one-off purchases — they create multi-year service, maintenance, and consumables supply chains that sustain procurement volumes well beyond the initial capital expenditure.
The market structure varies significantly by sub-category. Medical equipment procurement (CPV 33.1) tends toward high-value, low-frequency tenders where technical evaluation weighs heavily. Pharmaceutical procurement operates through centralised purchasing bodies and framework agreements that negotiate prices for entire hospital networks. Health services procurement spans everything from outsourced clinical services to public health campaigns, with procedure types ranging from open procedures for routine services to innovation partnerships for novel diagnostics and treatments.
The pandemic did not just create a spending spike — it permanently shifted procurement priorities. Resilience, supply chain diversification, and domestic manufacturing capacity are now embedded in healthcare procurement strategies across every EU member state. Suppliers whose value proposition includes supply security have a durable competitive advantage.
Germany dominates European healthcare procurement with 34,200+ procedures, reflecting its decentralised hospital system where over 1,900 hospitals independently procure equipment and services. The German market is characterised by high technical standards, strong preference for established manufacturers, and a complex landscape of purchasing groups (Einkaufsgemeinschaften) that aggregate demand across hospital networks. Average contract values (EUR 820K) are the highest among the top five markets, driven by the prevalence of large-scale imaging and surgical equipment tenders.
France is the second-largest market at 28,400 procedures, with procurement heavily centralised through hospital purchasing groups (GHT — Groupements Hospitaliers de Territoire) and the national purchasing agency UniHA. This centralisation creates larger, less frequent framework competitions that carry significant revenue for winners but require substantial bid investment. France has been particularly aggressive in digital health procurement, with its Espace Numérique de Santé programme driving demand for electronic health records, telemedicine platforms, and health data exchange infrastructure.
The growth stories in healthcare procurement come from Eastern Europe. Poland (up 14.6%), Romania (up 19.2%), and Czech Republic (up 11.8%) are experiencing rapid procurement growth driven by EU cohesion funds and recovery investments. These markets present both opportunity and challenge: volumes are growing fast and competition is lower than in Western Europe, but procurement practices can be less predictable, payment terms longer, and technical specifications more variable. For medical device suppliers with products already CE-marked, Eastern European markets offer a compelling volume-growth story. For a deeper look at these growth markets, see our analysis of fastest-growing procurement markets in Europe and the State of European Procurement 2026 report.
| country | key health segments | procurement model |
|---|---|---|
| Germany | Imaging, surgical systems, lab diagnostics | Decentralised + purchasing groups |
| France | Digital health, pharmaceuticals, devices | Centralised (UniHA, GHT) |
| Italy | Medical devices, hospital services | Regional (Consip + regional agencies) |
| Poland | Hospital equipment, infrastructure | EU-funded modernisation waves |
Healthcare procurement structures differ more between countries than in most other sectors. Germany's hospital-level purchasing, France's centralised groups, and Italy's regional model each demand different sales and bid strategies. A one-size-fits-all approach to European healthcare procurement is a reliable way to lose.
Within the broad healthcare procurement landscape, five categories command the majority of spend and merit individual analysis. Medical imaging equipment (MRI, CT, X-ray, and ultrasound systems) represents approximately 18% of healthcare procurement by value, despite comprising just 6% of procedures by count. These high-value, technically complex tenders typically use restricted procedures with pre-qualification stages, and evaluation criteria weight technical quality at 60-70% versus price at 30-40%. The market is concentrated among a small number of global manufacturers, but opportunities exist in maintenance, refurbishment, and peripheral equipment.
Pharmaceutical procurement operates on a fundamentally different model. Hospitals and health systems procure medicines through framework agreements negotiated by central purchasing bodies, with individual hospitals calling off against pre-agreed pricing. Duke's data shows pharmaceutical frameworks averaging 3-4 years in duration with typical ceiling values of EUR 10-50 million per therapeutic category. Generic and biosimilar competition is intensifying procurement pressure on originator manufacturers, while speciality medicines and advanced therapy medicinal products (ATMPs) are creating new, higher-value procurement channels.
The fastest-growing category is digital health, spanning electronic health records (EHR), telemedicine, clinical decision support, and health data analytics. This segment has grown 22% year-over-year and now represents approximately 8% of healthcare procurement by value. The European Health Data Space regulation, expected to be fully operational by 2027, is already driving procurement of interoperable data platforms and cross-border health record systems. Suppliers with HL7 FHIR-compliant solutions and experience navigating clinical workflow integration are positioned for sustained demand.
The healthcare procurement market is bifurcating. Traditional categories (devices, consumables, pharmaceuticals) are mature, price-competitive, and framework-dominated. Digital health is earlier in its lifecycle, specification-driven, and more open to innovation. Suppliers should assess which side of this divide their products fall on, because the winning strategies for each are fundamentally different.
Healthcare is the sector where EU innovation procurement mechanisms see the most active use. Pre-commercial procurement (PCP) and innovation partnerships — procedural tools designed to allow contracting authorities to develop and procure solutions that do not yet exist in the market — have found their natural home in health. Duke's data identifies 480+ innovation-oriented healthcare procedures in the analysis period, spanning AI-assisted diagnostics, point-of-care testing devices, remote patient monitoring systems, and antimicrobial resistance countermeasures.
The practical importance of innovation procurement goes beyond its current volume. These procedures serve as market-shaping mechanisms: they signal where public health priorities are heading, they establish technical requirements that influence future standard procurement, and they create reference customers for suppliers whose products are still early in their commercial lifecycle. The EU's Innovative Health Initiative and the European Innovation Council both fund demand-side procurement that directly creates buying opportunities for health technology companies.
For suppliers, the key to innovation procurement is early engagement. Unlike standard open procedures where specifications are fixed at publication, innovation procedures are explicitly designed for dialogue between buyers and suppliers during the procurement process. Market consultations, prior information notices, and industry days hosted by hospital purchasing groups are the primary channels through which innovative suppliers influence what gets bought. Suppliers who wait for the formal tender notice have already lost the specification-shaping battle.
Innovation procurement is not a niche — it is the leading edge of standard procurement. Today's PCP for AI-assisted radiology becomes tomorrow's EUR 200M framework for AI-enabled imaging software. Suppliers who engage in innovation procurement build the relationships and shape the specifications that give them lasting advantage when these technologies move to full-scale adoption.
| # | country | procedures | avg. value | yoy change |
|---|---|---|---|---|
| 1 | Germany | 34,200 | EUR 820K | +7.8% |
| 2 | France | 28,400 | EUR 640K | +9.2% |
| 3 | Italy | 21,600 | EUR 580K | +6.4% |
| 4 | Spain | 16,800 | EUR 430K | +8.1% |
| 5 | Poland | 12,400 | EUR 310K | +14.6% |
| 6 | Netherlands | 9,800 | EUR 920K | +5.3% |
| 7 | Belgium | 7,200 | EUR 710K | +6.9% |
| 8 | Sweden | 6,400 | EUR 550K | +4.7% |
| 9 | Romania | 5,800 | EUR 280K | +19.2% |
| 10 | Czech Republic | 4,600 | EUR 340K | +11.8% |
Duke monitors 300+ procurement sources across 25+ countries, covering 61M+ historical procedures. Our platform ingests notices daily from national portals, regional platforms, and EU-wide databases including TED. Every tender is normalised into a unified data model with standardised buyer identifiers, CPV codes, lot structures, geographic targeting, and award outcomes — enabling the cross-sector analysis that powers this report. Healthcare procedures are identified using CPV divisions 33 and 85, supplemented by analysis of related codes covering laboratory equipment (CPV 38), rehabilitation services, and medical facility construction.